CACamila Armirola-Ricaurte

Camila Armirola-Ricaurte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camila Armirola-Ricaurte has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantifying heritability in functional regions of the coding and non-coding genome across diverse individuals

    by Theo V. Lupu, Harrison I.W. Wright, Camila Armirola-Ricaurte, Alicia Huerta-Chagoya, Andrew R. Wood, Josep M. Mercader, Alisa K. Manning, Micah R. Hysong, Inês Barroso, Caroline F. Wright, et al.

    Most heritability studies have focused on common genetic variation and have largely excluded non-European or highly admixed populations. Here, we estimated the whole-genome heritability (h 2 WGS ) of seven complex traits using 73,600,953 autosomal and chromosome X variants for 198,931 unrelated individuals from three genetic similarity groups. Adjusting for population stratification, we showed that rare variants (minor allele frequency2 WGS . We used simulations to show how functionally-stratified heritability can be inflated due to linkage with missing or lower-quality variants. Finally, after accounting for confounding effects, we found substantial heritability enrichment from variants in non-coding RNA exons (maximum fold enrichment, FE=8.7, P =3.56e-7), UTRs (23.0, P =3.46e-30), distal regulatory regions (33.8, P =3.26e-42), and protein-coding exons (58.0, P =7.78e-15). Our study provides a framework for investigating the genetic architecture of complex human phenotypes using diverse whole-genome sequencing data and highlights the contribution of rare and non-coding genetic variants to the heritability of complex traits.

  • Open Access

    An ancestry-enriched PIEZO1 missense variant biases HbA1c-based diagnosis of prediabetes and type 2 diabetes in South Asians

    by Miriam Samuel, Daniel Stow, Vi Bui, Margherita Bigossi, Sam Hodgson, Susan Martin, Jana Soenksen, Camila Armirola-Ricaurte, Stuart Rison, Julia Cassasco-Zanini, et al.

    Background: Glycated haemoglobin (HbA1c) underpins type 2 diabetes (T2D) and prediabetes management worldwide and reflects both glycaemia and erythrocyte biology. A missense variant in PIEZO1 (rs563555492 T ), carried by 1 in 12 south Asians, has been associated with a nonglycemic reduction in HbA1c. We aimed to further characterise this association and evaluate its clinical consequences. Methods: We undertook genetic and linked health data analyses across two cohorts: 19,898 (37.4% female) South Indians from the Madras Diabetes Research Foundation (MDRF) and 43,011 (54.4% female) British Bangladeshis and British Pakistanis in Genes & Health. In MDRF, we tested associations with glycaemic and erythrocytic traits using additive genetic models. In Genes & Health we modelled diagnosis of prediabetes, T2D, and diabetic eye disease using flexible parametric survival models. Ten-year absolute risks were estimated for a population aged 40-50 years. Findings: PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c, but not with fasting glucose, postprandial glucose, or C-peptide. This variant reduced risk of prediabetes (HR 0·63, 95% CI 0·58-0·69) and T2D (0·85, 0·78-0·93) diagnosis, and increased risk of diabetic eye disease among individuals with T2D (1·20, 1·01-1·43). Modelling suggested approximately 1,019 missed prediabetes and 303 missed T2D diagnoses per 100,000 adults over 10 years. Interpretation: An ancestry enriched PIEZO1 variant is associated with lower HbA1c independent of glycaemia, reduced prediabetes and T2D diagnosis suggesting delayed detection, and increased complication risk. Reliance on HbA1c may systematically underestimate glycaemic risk in a substantial minority of south Asians. Funding: The Wellcome Trust; NIHR Research in Context: Evidence before this study: We searched PubMed from database inception to Nov 1, 2025, for studies examining PIEZO1, Glycated Haemoglobin (HbA1c) and type 2 diabetes (T2D) related outcomes. Search terms included “PIEZO1”, “haemoly*”, “hemol*”, “erythrocyte*”, “HbA1c”, “glycated haemoglobin”, “glycated hemoglobin”, “type 2 diabetes”, “prediabetes”, “retinopathy”, and related terms. HbA1c is widely used to guide prevention, diagnosis, and management of T2D, but variants affecting erythrocyte structure or lifespan can alter its relationship with glycaemia. A missense variant in PIEZO1 (rs563555492 T ), carried by one in twelve south Asians, has been associated with lower HbA1c and erythrocytic biomarkers without differences in fasting glucose and with older age at T2D diagnosis, suggesting delayed diagnosis in UK-based cohorts. However, uncertainties remain. Associations have not been replicated outside the UK to confirm generalisability. Experimental animal models suggest PIEZO1 channels may influence pancreatic insulin secretion, but this has not been evaluated in human cohorts. Finally, the potential clinical and health-economic consequences associated with this variant remain largely unexplored. Added value of this study: We replicated associations between rs563555492 T , lower HbA1c, and erythrocytic changes in a geographically distinct south Asian cohort based in South India. We found no association with fasting glucose, postprandial glucose, or C-peptide concentrations, supporting a predominantly erythrocytic mechanism. We examined the clinical and economic consequences of this variant on south Asians in a large UK population-based cohort, following introduction of HbA1c-based diagnostic criteria. Carriers experienced delayed diagnosis of prediabetes and T2D, and there was some evidence of increased risk of diabetic eye disease. In a modelled population aged 40-50 years, the variant was associated with approximately 1,019 missed prediabetes diagnoses and 303 missed T2D diagnoses per 100,000 adults over 10 years. Because prediabetes diagnosis initiates referral to prevention programmes, missed diagnoses represent lost opportunities for disease prevention. In a UK NHS setting, we estimated the associated opportunity cost to be between £970,000 - £1,390,000 per 100,000 individuals over a 10-year horizon. Implications of all the available evidence: A south Asian ancestry enriched PIEZO1 variant can disrupt the relationship between HbA1c and glycaemia and delay detection of prediabetes and T2D. Reliance on HbA1c alone may underestimate glycaemic risk in a substantial minority of individuals of south Asian ancestry, with potential implications for prevention strategies, risk of complications and health care costs. Alternative biomarkers of glycaemia or individualisation of HbA1c may help ensure timely and accurate diabetes detection in populations where this variant is common.

  • Open Access

    HbA1c-based diagnosis of type 2 diabetes and complication risk are distorted in British south Asians due to HbE thalassaemia trait

    by Sam Hodgson, Veline L'Esperance, Miriam Samuel, Moneeza Siddiqui, Daniel Stow, Camila Armirola-Ricaurte, Genes & Health Research Team, David A van Heel, Rohini Mathur, Trevelyan McKinley, et al.

    Background: Genetic variants impacting red blood cell biology disrupt the relationship between glycaemia and glycated haemoglobin (HbA1c), with implications for diagnosis and management of type 2 diabetes (T2D). Thalassaemia trait is estimated to affect 350 million people globally, but its impact on T2D and related outcomes is not clear. Methods: We explored associations between thalassaemia trait, HbA1c, and T2D diagnosis and complications in 43,088 British Bangladeshi and Pakistani participants in the Genes & Health study with linked multisource England National Health Service (NHS) electronic health record data and whole exome sequencing. Findings: 2,490 participants (5.8%) were heterozygous carriers of ClinVar pathogenic / likely pathogenic thalassaemia variants, however 3 in 4 of these were not diagnosed with thalassaemia in their NHS health records. rs33950507, a common variant causal for HbE thalassaemia, was associated with increased HbA1c (beta=0.13, 95%CI:0.08-0.18, p=7.8×10 −8 ), but not glucose levels (beta=0.01, 95%CI:-0.04-0.06, P=0.72). rs33950507 was associated with increased hazards of prediabetes (HR=1.38, 95%CI:1.26-1.52, p=2.2×10 −6 ) and T2D (HR=1.11, 95%CI:1.01-1.22, p=0.03), and reduced hazards of diabetic eye disease (HR=0.74, 95%CI:0.56-0.96, p=0.02) and cerebrovascular disease (HR=0.44, 95%CI:0.20-0.94, p=0.03). Sensitivity analyses suggested mediation by overdiagnosis and overtreatment of T2D. Interpretation: Alternatives to HbA1c, and/or precision medicine approaches to defining and managing pre-diabetes and T2D. These findings have global impact, and are particularly relevant to individuals from ancestral groups among whom erythrocytic traits are more common but often undiagnosed. Funding: Wellcome Trust, MRC, NIHR, Barts Charity, Genes & Health Industry Consortium RESEARCH IN CONTEXT: Evidence before this study: The role of genetic variants that disrupt red blood cell biology in distorting the relationship between glycaemia and glycated haemoglobin (HbA1c) is increasingly recognised. Recently, variants in G6PD and PIEZO1, associated with lower HbA1c via red blood cell mechanisms independent of blood glucose, have been shown to associate with increased progression of diabetes complications. The clinical consequences of HbA1C disruption from thalassaemia trait remain poorly understood, despite thalassaemia trait affecting 350 million individuals worldwide, and being known to interfere with HbA1c measurement. We searched PUBMED and EMBASE for “thalass* & (diabet* | “hba1” | glycat*)” from inception to December 2025, identifying 984 studies. While several studies described distortion of HbA1c relative to blood glucose in thalassaemia trait, we identified none which reported on the clinical consequences, or on the diagnosis of diabetes or its complications. Added value of this study: Thalassemia affects over 350 million people globally. We defined thalassaemia trait as individuals heterozygous for ClinVar pathogenic / likely pathogenic variants in whole exome sequence data in the Genes & Health study of British Pakistani and Bangladeshi individuals (n = 2,490 / 43,098). We highlight that only 1 in 4 of these genetically-defined thalassaemia trait carriers had a clinical diagnosis in their NHS health records, suggesting that thalassaemia is under-recognised in clinical practice in this population. A clinical prediction tool using routine. blood tests (ThalPred), was also only able to identify only one quarter of thalassaemia trait carriers. HbE thalassaemia trait was associated with increased HbA1c, contrasting to findings previously reported for G6PD and PIEZO1 which show opposite directionality. Thalassemia trait was also associated with increased hazards of prediabetes and type 2 diabetes (T2D) diagnosis, but was not associated with changes in serum glucose. HbE trait was associated with reduced hazards of complications including diabetic eye and cerebrovascular disease, but these associations were lost after adjustment for HbA1c, T2D diagnosis, and antidiabetic drug exposure. These findings suggest that the distortion of HbA1c leads to over-diagnosis and over-treatment, and this mediates the association with complications. Implications of all the available evidence: This study adds further evidence to a growing literature emphasising the distortion between HbA1c and glycaemia in genetic conditions affecting red cell biology. Our findings suggest there is need for alternatives to HbA1c, and/or precision medicine approaches, to diagnose and manage prediabetes and type 2 diabetes accurately and equitably. These findings are particularly relevant in Asian ancestral groups, among whom poorer diabetes outcomes and red cell traits such as thalassaemia are common.


  • Open Access

    Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

    by Camila Armirola-Ricaurte, Laura Morant, Isabelle Adant, Sherifa A Hamed, Menelaos Pipis, Stephanie Efthymiou, Silvia Amor-Barris, Derek Atkinson, Liedewei Van de Vondel, Aleksandra Tomic, et al.

    Defects in mitochondrial dynamics are a common cause of Charcot–Marie–Tooth disease (CMT), whereas primary deficiencies in the mitochondrial respiratory chain (MRC) are rare and atypical for this aetiology. This study aims to report COX18 as a novel CMT-causing gene. This gene encodes an assembly factor of mitochondrial Complex IV that translocates the C-terminal tail of MTCO2 across the mitochondrial inner membrane. Exome sequencing was performed in four affected individuals from three families. The patients and available family members underwent thorough neurological and electrophysiological assessment. The impact of one of the identified variants on splicing, protein levels and mitochondrial bioenergetics was investigated in patient-derived lymphoblasts. The functionality of the mutant protein was assessed using a proteinase K protection assay and immunoblotting. Neuronal relevance of COX18 was assessed in a Drosophila melanogaster knockdown model. Exome sequencing coupled with homozygosity mapping revealed a homozygous splice variant c.435–6A>G in COX18 in two siblings with early-onset progressive axonal sensorimotor peripheral neuropathy. By querying external databases, we identified two additional families with rare deleterious biallelic variants in COX18. All eight affected individuals presented with axonal CMT, and some patients also exhibited CNS symptoms, such as dystonia and spasticity. Functional characterization of the c.435-6A>G variant demonstrated that it leads to the expression of an alternative transcript that lacks exon 2, resulting in a stable but defective COX18 isoform. The mutant protein impairs Complex IV assembly and activity, leading to a reduction in mitochondrial membrane potential. Downregulation of the COX18 homologue in D. melanogaster resulted in signs of neurodegeneration, including locomotor deficit and progressive axonal degeneration of sensory neurons. Our study presents genetic and functional evidence that supports COX18 as a newly identified gene candidate for autosomal recessive axonal CMT with or without CNS involvement. These findings emphasize the significance of peripheral neuropathy within the spectrum of primary mitochondrial disorders, in addition to the role of mitochondrial Complex IV in the development of CMT. Our research has important implications for the diagnostic work-up of CMT patients.

  • Open Access

    Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

    by Camila Armirola-Ricaurte, Laura Morant, Isabelle Adant, Sherifa Ahmed Hamed, Menelaos Pipis, Stephanie Efthymiou, Silvia Amor-Barris, Derek Atkinson, Liedewei Van de Vondel, Aleksandra Tomic, et al.

    Defects in mitochondrial dynamics are a common cause of Charcot-Marie-Tooth disease (CMT), while primary deficiencies in the mitochondrial respiratory chain (MRC) are rare and atypical for this etiology. This study aims to report COX18 as a novel CMT-causing gene. This gene encodes an assembly factor of mitochondrial Complex IV (CIV) that translocates the C-terminal tail of MTCO2 across the mitochondrial inner membrane. Exome sequencing was performed in four affected individuals. The patients and available family members underwent thorough neurological and electrophysiological assessment. The impact of one of the identified variants on splicing, protein levels, and mitochondrial bioenergetics was investigated in patient-derived lymphoblasts. The functionality of the mutant protein was assessed using a Proteinase K protection assay and immunoblotting. Neuronal relevance of COX18 was assessed in a Drosophila melanogaster knockdown model. Exome sequencing coupled with homozygosity mapping revealed a homozygous splice variant c.435-6A>G in COX18 in two siblings with early-onset progressive axonal sensory-motor peripheral neuropathy. By querying external databases, we identified two additional families with rare deleterious biallelic variants in COX18 . All affected individuals presented with axonal CMT and some patients also exhibited central nervous system symptoms, such as dystonia and spasticity. Functional characterization of the c.435-6A>G variant demonstrated that it leads to the expression of an alternative transcript that lacks exon 2, resulting in a stable but defective COX18 isoform. The mutant protein impairs CIV assembly and activity, leading to a reduction in mitochondrial membrane potential. Downregulation of the COX18 homolog in Drosophila melanogaster displayed signs of neurodegeneration, including locomotor deficit and progressive axonal degeneration of sensory neurons. Our study presents genetic and functional evidence that supports COX18 as a newly identified gene candidate for autosomal recessive axonal CMT with or without central nervous system involvement. These findings emphasize the significance of peripheral neuropathy within the spectrum of primary mitochondrial disorders and the role of mitochondrial CIV in the development of CMT. Our research has important implications for the diagnostic workup of CMT patients.


  • Open Access

    Alternative splicing expands the clinical spectrum of NDUFS6-related mitochondrial disorders

    by Camila Armirola-Ricaurte, Noortje Zonnekein, Georgios Koutsis, Silvia Amor-Barris, Ana Lara Pelayo-Negro, Derek Atkinson, Stephanie Efthymiou, Valentina Turchetti, Argyris Dinopoulos, Antonio Garcia, et al.


  • Genome sequencing and comprehensive rare-variant analysis of 465 families with neurodevelopmental disorders

    by Alba Sanchis-Juan, Karyn Megy, Jonathan Stephens, Camila Armirola Ricaurte, Eleanor Dewhurst, Kayyi Low, Courtney E. French, Detelina Grozeva, Kathleen Stirrups, Marie Erwood, et al.


  • Open Access

    Genome Sequencing and Comprehensive Rare Variant Analysis of 465 Families with Neurodevelopmental Disorders

    by Alba Sanchis-Juan, Karyn Megy, Jonathan Stephens, Camila Armirola Ricaurte, Eleanor Dewhurst, Kayyi Low, Courtney E French, Detelina Grozeva, Kathleen Stirrups, Marie Erwood, et al.

    Purpose Despite significant progress in unravelling the genetic causes of neurodevelopmental disorders (NDDs), a substantial proportion of individuals with NDDs remain without a genetic diagnosis following microarray and/or exome sequencing. Here we aimed to assess the power of short-read genome sequencing (GS), complemented with long-read GS, to identify causal variants in NDD participants from the NIHR BioResource project. Methods Short-read GS was conducted on 692 individuals (489 affected and 203 unaffected relatives) from 465 families. Additionally, long-read GS was performed on five affected individuals who had structural variants (SVs) in technically challenging regions, complex SVs, or required distal variant phasing. Results Causal variants were identified in 36% affected individuals (177/489) and a further 26% (129/489) had a variant of uncertain significance, after multiple rounds of re-analysis. Among all reported variants, 88% (333/380) were SNVs/indels, and the remainder were structural variants (SVs), non-coding, and mitochondrial variants. Furthermore, long-read GS facilitated resolution of challenging SVs and invalidated variants of difficult interpretation from short-read GS. Conclusion This study demonstrates the value of short-read GS, complemented with long-reads, to investigate the genetic causes of NDDs. GS provides a comprehensive and unbiased method to identify all types of variants throughout the nuclear and mitochondrial genome in NDD individuals.